AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, raised $5 million by offering 0.96 million shares at $5.50. AzurRX Biopharma plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1 Financial Securities acted as lead managers on the deal.
